全文获取类型
收费全文 | 861篇 |
免费 | 43篇 |
国内免费 | 62篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 24篇 |
妇产科学 | 23篇 |
基础医学 | 122篇 |
口腔科学 | 8篇 |
临床医学 | 129篇 |
内科学 | 185篇 |
皮肤病学 | 10篇 |
神经病学 | 79篇 |
特种医学 | 93篇 |
外科学 | 57篇 |
综合类 | 25篇 |
预防医学 | 22篇 |
眼科学 | 6篇 |
药学 | 85篇 |
中国医学 | 1篇 |
肿瘤学 | 62篇 |
出版年
2022年 | 3篇 |
2021年 | 9篇 |
2020年 | 5篇 |
2019年 | 10篇 |
2018年 | 10篇 |
2017年 | 10篇 |
2016年 | 9篇 |
2015年 | 16篇 |
2014年 | 14篇 |
2013年 | 25篇 |
2012年 | 24篇 |
2011年 | 30篇 |
2010年 | 23篇 |
2009年 | 26篇 |
2008年 | 18篇 |
2007年 | 53篇 |
2006年 | 25篇 |
2005年 | 34篇 |
2004年 | 24篇 |
2003年 | 21篇 |
2002年 | 24篇 |
2001年 | 21篇 |
2000年 | 30篇 |
1999年 | 25篇 |
1998年 | 31篇 |
1997年 | 42篇 |
1996年 | 31篇 |
1995年 | 26篇 |
1994年 | 14篇 |
1993年 | 25篇 |
1992年 | 17篇 |
1991年 | 22篇 |
1990年 | 34篇 |
1989年 | 39篇 |
1988年 | 26篇 |
1987年 | 22篇 |
1986年 | 21篇 |
1985年 | 18篇 |
1984年 | 16篇 |
1983年 | 12篇 |
1982年 | 7篇 |
1981年 | 10篇 |
1980年 | 13篇 |
1979年 | 6篇 |
1978年 | 8篇 |
1976年 | 7篇 |
1975年 | 7篇 |
1974年 | 4篇 |
1970年 | 3篇 |
1969年 | 3篇 |
排序方式: 共有966条查询结果,搜索用时 0 毫秒
21.
22.
Mice are a widely utilized in vivo model for translational salivary gland research but must be used with caution. Specifically, mouse salivary glands are similar in many ways to human salivary glands (i.e., in terms of their anatomy, histology, and physiology) and are both readily available and relatively easy and affordable to maintain. However, there are some significant differences between the two organisms, and by extension, the salivary glands derived from them must be taken into account for translational studies. The current review details pertinent similarities and differences between human and mouse salivary glands and offers practical guidelines for using both for research purposes. 相似文献
23.
24.
25.
Muringampurath-John D Jaye DL Flowers CR Saxe D Chen Z Lechowicz MJ Weisenburger DD Bast M Arellano ML Bernal-Mizrachi L Heffner LT McLemore M Kaufman JL Winton EF Lonial S Armitage JO Khoury HJ 《British journal of haematology》2012,158(5):608-614
Diffuse large B‐cell lymphoma (DLBCL) occasionally presents with circulating malignant cells. The clinical characteristics and long‐term outcomes of these patients have not been described. Twenty‐nine newly diagnosed DLBCL presenting in leukaemic phase were identified between 1996 and 2010, at two institutions. Median age was 48 years, and patients presented with leucocytosis, high lactate dehydrogenase levels, B symptoms, and high International Prognostic Index score. Extra nodal site involvement was observed in all patients and affected the bone marrow (100%), spleen (62%), pleura/lung (41%), liver (21%), bone (17%), bowels (7%) and cerebrospinal fluid (14%). Blood lymphomatous cells co‐expressed CD19, CD20, CD22, CD38, CD45, HLA‐DR and FMC7 in >90%, and kappa or lambda light chain restriction in >50%. Ninety per cent received rituximab and anthracycline‐based chemotherapy. Overall, remission was complete in 54% and partial in 31%; 15% had resistant disease. Median follow‐up was 47 months; 13 (45%) patients remain alive in complete remission. Median progression‐free and overall survivals were 11·5 and 46·7 months, respectively. In summary, patients with DLBCL in leukaemic phase present with high tumour burden and frequent involvement of extra nodal sites. In this uncommon DLBCL subgroup, anthracycline‐based regimens with rituximab are associated with early morbidity and mortality, but yield approximately 50% 4‐year survival. 相似文献
26.
Sahaphume Srisuma Dazhe Cao Kurt Kleinschmidt Alan C. Heffner Eric J. Lavonas 《Clinical toxicology (Philadelphia, Pa.)》2016,54(5):441-446
Introduction: Although most poisoning deaths are not preventable with current medical technology, in some cases different management decisions may have prevented fatal outcomes. Objective: This study aims to review reported poisoning-related deaths for preventability to provide insight to improve future care. Methods: Fatality abstracts published in the US National Poison Data System (NPDS) Annual Reports (2008–2012) were analyzed. Preventability was graded using a Likert scale of 1 (definitely non-preventable) to 6 (definitely preventable). Two medical toxicologists screened all cases. Cases deemed definitely not preventable (score 1) by both reviewers were excluded from further review and considered to be “non-preventable”. All cases considered at least possibly preventable by either screener were reviewed by a multidisciplinary panel of 5 physicians for preventability scoring. Differences were resolved by consensus. Cases determined to be “preventable” (scores 4–6) were characterized by type of improvement issue involved (diagnosis, treatment, monitoring, other) and recurring scenarios. Results: Of 390 published abstracts, 78 (20.0%) deaths were considered at least possibly preventable by at least one screener. Of these, 34 (8.7%) deaths were determined to be “preventable” by the panel. Inter-observer agreement by weighted kappa analysis was 0.58 for screening, 0.24 for preventability, and 0.44 for specific aspects of care. The most common toxicants were salicylates (n?=?9), opioids (n?=?4), toxic alcohols (n?=?3), fluoride containing product (n?=?3), and bupropion (n?=?3). The most common improvement opportunities involved treatment and monitoring. Discussion: Most of the ingested substances in preventable deaths have delayed GI absorption or require metabolic activation to produce a delayed effect (such as salicylates, opioids, and toxic alcohols), and therefore provide an opportunity for early recognition and successful interventions. Most improvement opportunities are clearly described in the literature but may be not recognized. Conclusions: Based on an analysis of published NPDS data, a considerable number of poisoning-related deaths reaching medical attention may be preventable. The most common scenarios involved in potentially preventable poisoning fatalities related to monitoring and treatment. Salicylates and opioids were the most common agents involved in preventable deaths. 相似文献
27.
28.
29.
Gazitt Y; Tian E; Barlogie B; Reading CL; Vesole DH; Jagannath S; Schnell J; Hoffman R; Tricot G 《Blood》1996,87(2):805-811
Peripheral blood stem cells (PBSCs) mobilized with high-dose chemotherapy and hematopoietic growth factors are now widely used to support myeloablative therapy of multiple myeloma and effect complete remissions in up to 50% of patients with apparent extension of event- free and overall survival. Because tumor cells are present not only in bone marrow, but also in virtually all PBSC harvests, it is conceivable that autografted myeloma cells contribute to relapse after autotransplants. In this study, the kinetics of mobilization of normal hematopoietic stem cells were compared with those of myeloma cells present in PBSC harvests of 12 patients after high-dose cyclophosphamide and granulocyte-macrophage colony-stimulating factor administration. CD34+ and CD34+Lin-Thy+ stem cell contents were measured by multiparameter flow cytometry, and myeloma cells were quantitated by immunostaining for the relevant Ig light chain and by a quantitative polymerase chain reaction for the myeloma-specific CDRIII sequence. Results indicated marked heterogeneity in the percentages of mobilized stem cells among different patients (0.1% to 22.2% for CD34+ cells and 0.1% to 7.5% for CD34+Lin-Thy+ cells, respectively). The highest proportions of hematopoietic progenitor cells were observed early during apheresis, with 9 of 12 patients mobilizing adequate amounts of CD34+ cells for 2 autotransplants (> 4 x 10(6)/kg) within the first 2 days, whereas peak levels (percent and absolute numbers) of myeloma cells were present on days 5 and 6 (0.5% to 22.0%). During the last days of collection, mobilized tumor cells exhibited more frequently high labeling index values (1% to 10%; median, 4.4%) and an immature phenotype (CD19+). The differential mobilization observed between normal hematopoietic stem cells and myeloma cells can be exploited to reduce tumor cell contamination in PBSC harvests. 相似文献
30.
Etoposide is one of the most widely used antineoplastics. Unfortunately, the same treatment schedules associated with impressive efficacy are associated with an increased risk of secondary acute myeloid leukemia (AML), which has prompted its withdrawal from some treatment regimens, thereby potentially compromising efficacy against the original tumor. Because etoposide-associated AML is characterized by site-specific illegitimate DNA recombination, we studied whether etoposide could directly cause site-specific deletions of exons 2 and 3 in the hprt gene. Human lymphoid CCRF-CEM cells were treated with etoposide for 4 hours, and DNA was isolated after subculturing. The deletion of exons 2 and 3 from hprt was assayed by a quantitative polymerase chain reaction (PCR) method. In the absence of etoposide treatment, the frequency of deletions of exons 2 and 3 was very low (5.05 x 10(-8)). After exposure to 10 mumol/ L etoposide, the frequency of the exon 2 + 3 deletion was increased immediately after and at 24 hours after etoposide treatment (65 to 89 x 10(-8)) and increased to higher levels (128 to 173 x 10(-8)) after 2 and 6 days of subculture (P < .001 overall). The frequency of the exon 2 + 3 deletion assessed at 6 days of subculture after 4 hours of 0, 0.25, 1, 2.5, 5, and 10 mumol/L etoposide treatment increased with etoposide concentration, ie, 5.05 x 10(-8), 89.2 x 10(-8), 108 x 10(-8), 142 x 10(-8), 163 x 10(-8), and 173 x 10(-8), respectively (P < .0001). Sequencing of a subset of amplified products confirmed the presence of DNA sequences at the breakpoints consistent with V(D)J recombination. By contrast, exon 2 + 3 deletions after etoposide treatment in the myeloid cell lines KG-1A and K562 showed no evidence of V(D)J recombinase in their genesis. We conclude that etoposide can induce the illegitimate site-specific action of V(D)J recombinase on an unnatural DNA substrate after a single treatment in human lymphoid cells. 相似文献